Prevalence of Dyslipidemias in Three Regions in Venezuela: The VEMSOLS Study Results

Abstract

Background:

The prevalence of dyslipidemia in multiple regions of Venezuela is unknown. The Venezuelan Metabolic Syndrome, Obesity and Lifestyle Study (VEMSOLS) was undertaken to evaluate cardiometabolic risk factors in Venezuela.

Objective:

To determine the prevalence of dyslipidemia in five populations from three regions of Venezuela.

Methods:

During the years 2006 to 2010, 1320 subjects aged 20 years or older were selected by multistage stratified random sampling from all households in five municipalities from 3 regions of Venezuela: Lara State (Western region), Merida State (Andean region), and Capital District (Capital region). Anthropometric measurements and biochemical analysis were obtained from each participant. Dyslipidemia was defined according to the NCEP/ATPIII definitions.

Results:

Mean age was 44.8 ± 0.39 years and 68.5% were females. The prevalence of lipids abnormalities related to the metabolic syndrome (low HDL-c [58.6%; 95% CI 54.9 - 62.1] and elevated triglycerides [39.7%; 36.1 - 43.2]) were the most prevalent lipid alterations, followed by atherogenic dyslipidemia (25.9%; 22.7 - 29.1), elevated LDL-c (23.3%; 20.2 - 26.4), hypercholesterolemia (22.2%; 19.2 - 25.2), and mix dyslipidemia (8.9%; 6.8 - 11.0). Dyslipidemia was more prevalent with increasing body mass index.

Conclusion:

Dyslipidemias are prevalent cardiometabolic risk factors in Venezuela. Among these, a higher prevalence of low HDL is a condition also consistently reported in Latin America.

Keywords:
Dyslipidemias / epidemiology; Cardiovascular Diseases; Risk Factors; Stroke / mortality; Obesity; Metabolic Syndrome

Resumo

Fundamento:

A prevalência de dislipidemia em várias regiões da Venezuela é desconhecida. A Síndrome Metabólica venezuelana, Obesidade e Estilo de Vida Estudo (VEMSOLS) foram realizados para avaliar os fatores de risco cardiometabólico na Venezuela.

Objetivo:

Determinar a prevalência de dislipidemia em cinco populações de três regiões da Venezuela.

Métodos:

Durante os anos de 2006 a 2010, 1320 indivíduos com 20 anos ou mais foram selecionados por amostragem aleatória estratificada de vários estágios de todas as famílias em cinco municípios a partir de 3 regiões da Venezuela: Estado Lara (região Oeste), Estado de Mérida (região andina) e Capital Distrito (região Capital). medidas antropométricas e análise bioquímica foram obtidas de cada participante. Dislipidemia foi definida de acordo com as definições NCEP / ATPIII.

Resultados:

A idade média foi de 44,8 ± 0,39 anos, e 68,5% eram do sexo feminino. A prevalência de lípidos anormalidades relacionadas à síndrome metabólica (HDL-c baixo [58,6%; IC95% 54,9-62,1] e triglicerídeos elevados [39,7%; 36,1-43,2]) foram as alterações lipídicas mais prevalente, seguida pela dislipidemia aterogênica ( 25,9%; 22,7-29,1), LDL-C elevado (23,3%; 20,2-26,4), hipercolesterolêmica (22,2%; 19,2-25,2), e misturar dislipidemia (8,9%; 6,8-11,0). Dislipidemia foi mais prevalente com o aumento do índice de massa corporal.

Conclusão:

As dislipidemias são fatores de risco cardiometabólico prevalentes na Venezuela. Entre elas, uma maior prevalência de baixo HDL é uma condição também consistentemente relatada na América Latina.

Palavras-chave:
Dislipidemias / epidemiologia; Doenças Cardiovasculares; Fatores de Risco; Acidente Vascular Cerebral / mortalidade; Obesidade; Síndrome Metabólica

Introduction

In Venezuela, cardiovascular disease (CVD), represented by ischemic heart disease (16.3%) and stroke (7.7%), was the major cause of death in 2012.¹ Both are strongly related with modifiable risk factors. According to the INTERHEART² and the INTERSTROKE³ studies, dyslipidemias, assessed as increased levels of apolipoprotein (ApoB/ApoA1 ratio), represented the 49.2% and the 25.9% of the attributable risk for acute myocardial infarction and stroke, respectively. Randomized controlled clinical trials have consistently demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) with statin therapy reduces the incidence of heart attack and ischemic stroke. For every 38.6 mg/dL LDL-c reduction, the annual rate of major vascular events decreases to one-fifth.⁴

Studies evaluating the prevalence of dyslipidemias in Venezuela have been compiled.⁵ However, most of them have small samples, and only two are representative of a city or a state. In 1,848 adults from the city of Barquisimeto, in the western region of the country, the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study⁶ reported the lowest prevalence of hypercholesterolemia (cholesterol ≥ 240 mg/dL) observed in Latin America (5.7%).⁶ In 3,108 adults from the state of Zulia, Florez et al.⁷ documented the prevalence of atherogenic dyslipidemia (high triglycerides and low levels of high- density lipoprotein of cholesterol [HDL-c]) in 24.1%. This number was higher in men than women, and increased with age. No study in Venezuela has included more than one region, prompting the design of the Venezuelan Metabolic Syndrome, Obesity and Lifestyle Study (VEMSOLS). This paper presents the results of VEMSOLS, specifically the prevalence of dyslipidemia in five populations of three regions in Venezuela.

Methods

Design and Subjects

An observational, cross-sectional study was designed to determine the prevalence of cardiometabolic risk factors in a sub-national sample of Venezuela. Five municipalities from three regions were evaluated: Palavecino, in Lara State (urban), from the Western region; Ejido (Merida city), in Merida State (urban), and Rangel (Páramo area), in Merida State (rural), both from the Andes region; Catia La Mar, in Vargas state (urban), and Sucre, in the Capital District (urban), both from the Capital region. From 2006 to 2010, a total of 1,320 subjects aged 20 years or more, who had lived in their houses for at least six months, were selected by a two-stage random sampling. Three different geographic regions of the country - Andes, mountains at the south; Western, llanos in the middle; and the Capital District, coast at the north - were assessed. Each region was stratified by municipalities and one was randomly selected. A map and a census of each location were required to delimit the streets or blocks, and to select the households to visit in each municipality. After selecting the sector to be surveyed in each location, the visits to households started from number 1 onwards, skipping every two houses. Pregnant women and participants unable to stand up and/or communicate verbally were excluded. All participants signed the informed consent form for participation.

The sample size was calculated to detect the prevalence of hypercholesterolemia (the lowest prevalent condition reported in Venezuela) in 5.7%⁶, with standard deviation of 1.55%, which allows to calculate the 95% confidence interval (95% CI). The minimal estimated number of subjects to be evaluated was 830. Overall, 1,320 subjects were evaluated (89.4% from the urban and 10.6% from the rural area).

Clinical and biochemical data

All subjects were evaluated in their households or in a nearby health center by a trained health team according to a standardized protocol. Each home was visited twice. In the first visit, the participants received information about the study and signed the written informed consent form. Demographic and clinical information was obtained using a standardized questionnaire. Weight was measured with as few clothes as possible, without shoes, using a calibrated scale. Height was measured using a metric tape on the wall. Waist circumference was measured with a metric tape at the iliac crest at the end of the expiration. Body mass index was calculated (BMI: weight[kg]/height[m]²).

In the second visit, blood samples were drawn after 12 hours of overnight fasting. Then, they were centrifuged for 15 minutes at 3000 rpm, within 30-40 minutes after collection, and transported with dry ice to the central laboratory, where they were properly stored at -40ºC until analysis. Data from participants who were absent during the first visit were collected. Total cholesterol,⁸ triglycerides,⁹ LDL-c, and HDL-c¹⁰ were determined by standard enzymatic colorimetric methods.

Categorization of variables

Dyslipidemia was defined according the National Cholesterol Education Program /Adult Treatment Panel III (NCEP/ATPIII)¹¹, being categorized in 6 types. Of these, four were isolated dyslipidemias: Low HDL-c (hyperalphalipoproteinemia) < 40 mg/dL in men and < 50 mg/dL in women; high triglycerides: ≥ 150 mg/dL; hypercholesterolemia (≥ 240 mg/dL of total cholesterol); high LDL-c ≥ 160 mg/dL; and two were combined dyslipidemias: atherogenic dyslipidemia (triglycerides ≥ 150 mg/dL + low HDL-c) and mixed dyslipidemia (triglycerides ≥ 150 mg/dL + total cholesterol ≥ 240 mg/dL). Additionally, individuals were classified according to BMI as normal weight (BMI < 25 kg/m²), overweight (BMI ≥ 25 kg/m² and < 30 kg/m²), or obese (BMI ≥ 30 kg/m²).¹² Abdominal obesity was established by waist circumference ≥ 94 cm in men and ≥ 90 cm in women.¹³

Statistical analysis

All calculations were performed using the SPSS 20 software (IBM corp. Released 2011. Armonk, NY: USA). It was verified that all variables had normal distribution using a normality test (Kolmogorov-Smirnov). All variables were continuous and data were presented as mean ± standard deviation (SD). Differences between mean values were assessed with the t-test. Proportions of subjects with dyslipidemia were presented as prevalence rates and 95% confidence intervals (CI). A Chi-square test was applied to compare different frequencies by gender, nutritional status and abdominal obesity. P-value of < 0.05 was considered statistically significant.

Results

Characteristics of the subjects

Two thirds of the study subjects were female. Men had higher triglycerides, waist circumference and lower HDL-c than women (Table 1). Age, BMI, total cholesterol and LDL-c were similar.

Table 1
Subject Characteristics

	Men	Women	Total	Significance
Participants (n, %)	412 (31.2)	908 (68.8)	1320 (100)
Age (years)	45.8 ± 14.8	44.4 ± 14.0	44.8 ± 14.3	NS
Body mass index (kg/m2)	27.7 ± 5.0	27.6 ± 5.3	27.6 ± 5.2	NS
Waist circumference (cm)	96.6 ± 13.2	89.8 ± 12.3	91.9 ± 13.0	< 0.0001
High density lipoprotein (HDL-c) (mg/dL) *	43.2 ± 10.4	47.2 ± 10.9	45.9 ± 10.9	NS
Triglycerides (mg/dL)	175.3 ± 154.7	140.0 ± 87.3	151.0 ± 114.3	< 0.0001
Total cholesterol (mg/dL)	207.7 ± 46.5	206.3 ± 47.6	206.7 ± 47.2	NS
Low density lipoprotein (LDL-c) (mg/dL)	131.0 ± 43.4	131.4 ± 43.8	131.3 ± 43.7	NS

• Data are mean ± SD. Gender differences according t-test.

Prevalence of dyslipidemia

Low HDL-c was the most prevalent lipid change present in nearly seven of ten women, and in about four of ten men (p < 0.01), followed by high triglycerides that were present in half of the men and in one third of women (p < 0.01). Their combination, atherogenic dyslipidemia, was observed in 25.9% of subjects, followed in frequency by increasing LDL-c and total cholesterol levels (Table 2). Mixed dyslipidemia was observed in only 8.9% of the subjects, and was higher among men than in women. An increasing prevalence of all types of dyslipidemias was found when individuals were classified according to BMI and at the presence of abdominal obesity (Figure 1 and Figure 2). The prevalence of hypercholesterolemia, high LDL-c and mixed dyslipidemia were similar in overweight and obese subjects, but higher than those found in the normal weight group.

Table 2
Prevalence of Dyslipidemias by Gender

	Men	Women	Total	Significance
	412	908	1320
Low HDL-c (< 40 mg/dL in men and < 50 mg/dL in women)	42.2 (38.6 – 45.8)	66.0 (62.5 – 69.4)	58.6 (54.9 – 62.1)	< 0.0001
Elevated triglycerides (≥ 150 mg/dL)	49.5 (45.8 – 53.1)	35.2 (31.7 – 38.7)	39.7 (36.1 – 43.2)	< 0.0001
Hypercholesterolemia (≥ 240 mg/dL)	23.8 (20.7 – 26.8)	21.5 (18.5 – 24.5)	22.2 (19.2 – 25.2)	NS
Elevated LDL-c (≥ 160 mg/dL)	22.8 (19.8 – 25.9)	23.5 (20.5 – 26.6)	23.3 (20.2 – 26.4)	NS
Atherogenic dyslipidemia (triglycerides ≥ 150 mg/dL + low HDL-c)	25.2 (22.1 28.0)	26.2 (23.0 – 29.4)	25.9 (22.7 – 29.1)	NS
Mixed dyslipidemia (triglycerides ≥ 150 + cholesterol ≥ 240 mg/dL)	12.4 (9.9 – 14.7)	7.4 (5.5 – 9.3)	8.9 (6.8 – 11.0)	0.002

• Data are showed in percentage (95% CI). Gender differences according to the Chi-square test.

Figure 1
Prevalence of dyslipidemia by nutritional status.

*Difference in the prevalence of dyslipidemia according to nutritional status using Chi-square (p < 0.01). High triglycerides: 150 mg/dL; low HDL-c: < 40 mg/dL in men and < 50 mg/dL in women; atherogenic dyslipidemia: triglycerides = 150 mg/dL + low HDL-c; hypercholesterolemia: total cholesterol = 240 mg/dL; elevated LDL-c: = 160 mg/dL; mixed dyslipidemia: triglycerides = 150 + total cholesterol = 240 mg/dL.

Figure 2
Prevalence of dyslipidemias by abdominal obesity (waist circumference = 94 cm in men and = 90 cm in women).

Significant difference of the prevalence of dyslipidemia between abdominal obesity or normal waist circumference *(p < 0.001) †(p = 0.002). High triglycerides = 150 mg/dL; Low HDL-c < 40 mg/dL in men and < 50 mg/dL in women; Atherogenic dyslipidemia triglycerides =150 mg/dL + low HDL-c; Hypercholesterolemia =240 mg/dL; Elevated LDL-c = 160 mg/dL; Mix dyslipidemia triglycerides = 150 + cholesterol = 240 mg/dL.

Discussion

The present study reports that the most prevalent lipid abnormality in our sub-national sample of adults in Venezuela is the low HDL-c (58.6%), followed by high triglycerides (38.7%), whereas the prevalence of hypercholesterolemia (22%) and its combination with hypertriglyceridemia (8.9%) were lower. Similar findings have been reported in earlier studies, both in Venezuela (Zulia state, Low HDL-c 65.3%, high triglycerides 32.3%),⁷ and Mexico (Low-HDL 48.4% and high triglycerides 42.3%).¹⁴ Using a cut-off point similar to that in our study, an extremely high prevalence of hypoalphalipoproteinemia has been also observed in Valencia city (90%)¹⁵ and the Junquito municipality (81.1%),¹⁶ both in the central region of Venezuela. Similarly to the observed in men in our study (49.5%), the aforementioned studies in Valencia and Junquito also reported high prevalence of elevated triglycerides (51%).^15,16 Most of these results are consistent with previous findings in the Latin America region. In a systematic review of metabolic syndrome in Latin America, the most frequent change was low HDL-c in 62.9% of the subjects.¹⁷

Although hypercholesterolemia (22.2%) is significantly less common compared with the aforementioned alterations, it was higher than the CARMELA study (5.7%) in Barquisimeto,⁶ and similar to that observed in Valencia (19.0%).¹⁵ Therefore, hypercholesterolemia remains as a cardiovascular risk factor to be considered when implementing public health measures in the Venezuelan population. Other of our findings are consistent with previous studies reporting that the prevalence of dyslipidemia increases with adiposity, and subjects with overweight/obesity^14,18 and abdominal obesity¹⁸ show worse lipid profiles than subjects of normal weight. As in our study, higher figures of elevated triglycerides in male,^14,18 and no differences between overweight and obese subjects when grouped according to BMI,¹⁴ have been reported.

Dyslipidemias can be caused by both genetic and environmental factors (obesity, smoking, low physical activity). In our study, the prevalence of low HDL-c without other lipid abnormalities was 29.2% (male 15%, female 35.7%). Of these, those with low HDL-c and normal weight (total 10.6%, male 5.3%, female 13.0%) could suggest the proportion of cases of hypoalphalipoproteinemia that could be associated with genetic factors. Also, part of the prevalence of low HDL-c in this population can be explained by metabolic factors (i.e., insulin resistance), a condition that produces modifications in more than one lipid sub-fraction. In fact, the prevalence of atherogenic dyslipidemia (25.9%) in our study was significant and remarkably similar to that reported by Florez et al.⁷ in the Zulia region (24.1%). Atherogenic dyslipidemia is the pattern most frequently observed in subjects with metabolic syndrome and insulin resistance, and both abnormalities are components of the metabolic syndrome definition. Besides genetic or metabolic factors, environmental adverse conditions are also important in Venezuela. The factors involving nutritional transition promoted inappropriate eating and lifestyle patterns in Venezuela and other Latin American countries, clearly contributing with the incidence of non-communicable diseases, especially those related to obesity and diabetes.¹⁹ A follow-up survey of food consumption, based on the food purchase, reported that caloric intake and the selection of foods with lower quality have increased in Venezuela.²⁰ A high rate of physical inactivity (68%) has also been reported in Venezuela in two studies involving 3,422 adults.⁵

Successful dietary strategies to reduce dyslipidemias and other metabolic syndrome components should include energy restriction and weight loss, manipulation of dietary macronutrients, and adherence to dietary and lifestyle patterns, such as the Mediterranean diet and diet/exercise.²¹ After the evaluation of the typical food-based eating and physical activity pattern in the Venezuelan population, culturally-sensitive adaptations of the Mediterranean diet with local foods and physical activity recommendations have been proposed.^5,22 Specific recommendations for patients with dyslipidemia have been also included in local clinical practice guidelines.²³

Some limitations can be observed in the present study. The sample did not represent the entire population of the country; only three of the eight regions of Venezuela were included. Additionally, in the VEMSOLS, eating pattern and physical activity were not investigated. The cut-off point for low HDL and triglycerides used was established for the metabolic syndrome definition, which can limit the comparison with other studies using a level below 35¹⁴ or 40¹⁸ mg/dL to define hypoalphalipoproteinemia. However, despite these limitations, this study is the first report of dyslipidemias in more than one region of Venezuela. A national survey in Venezuela in ongoing (Estudio Venezolano de Salud Cardiometabólica, EVESCAM study). Data collection will be completed in 2017.

Conclusions

This is the first report presenting the prevalence of dyslipidemia in more than one region of Venezuela. The results observed are consistent with other Latin American studies, reporting low HDL-c as the most frequent lipid alteration in the region. Additionally, high levels hypercholesterolemia were observed. Both conditions could be related with CVD, which represent a major public health problem in the region. A suggestion resulting from our findings is to monitor a complete lipid profile during medical check-ups, because in some Latin-American countries it is common to check only total cholesterol. The triggers of these changes need to be determined in future studies. The implementation of strategies focused in proper nutrition, more physical activity and avoiding weight gain is imperative.

• Sources of Funding
  There were no external funding sources for this study.
• Study Association
  This study is not associated with any thesis or dissertation work.
• Ethics approval and consent to participate
  This article does not contain any studies with human participants or animals performed by any of the authors.

References

• ¹
  World Health Organization. (WHO). Global Health Observatory Data Repository country views. Venezuela (Bolivarian Republic of) statistics summary (2002 - present) [Internet]. [Accessed in 2015 Aug 6]. Available from: http://apps.who.int/gho/data/node.country.country-VEN?lang=en
  » http://apps.who.int/gho/data/node.country.country-VEN?lang=en
• ²
  Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9.
  » https://doi.org/10.1016/S0140-6736(04)17018-9
• ³
  O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-23. doi: 10.1016/S0140-6736(10)60834-3.
  » https://doi.org/10.1016/S0140-6736(10)60834-3
• ⁴
  Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5.
  » https://doi.org/10.1016/S0140-6736(10)61350-5
• ⁵
  Nieto-Martinez R, Hamdy O, Marante D, Marulanda MI, Marchetti A, Hegazi RA, et al. Transcultural diabetes nutrition algorithm (tDNA): Venezuelan application. Nutrients. 2014;6(4):1333-63. doi: 10.3390/nu6041333.
  » https://doi.org/10.3390/nu6041333
• ⁶
  Schargrodsky H, Hernandez-Hernandez R, Champagne BM, Silva H, Vinueza R, Silva Aycaguer LC, et al; CARMELA Study Investigators. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med. 2008;121(1):58-65. doi: 10.1016/j.amjmed.2007.08.038.
  » https://doi.org/10.1016/j.amjmed.2007.08.038
• ⁷
  Florez H, Silva E, Fernandez V, Ryder E, Sulbaran T, Campos G, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005;69(1):63-77. doi: 10.1016/j.diabres.2004.11.018.
  » https://doi.org/10.1016/j.diabres.2004.11.018
• ⁸
  Roeschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem. 1974;12(5):226. PMID: 4440114.
• ⁹
  Wahlefeld A, Hu B. Methods of enzymatic analysis. New York: Academic Press Inc; 1974.
• ¹⁰
  Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995;41(5):717-23. PMID: 7729051.
• ¹¹
  National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. PMID: 12485966.
• ¹²
  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S. PMID: 9813653. Erratum in: Obes Res 1998;6(6):464.
• ¹³
  Aschner P, Buendia R, Brajkovich I, Gonzalez A, Figueredo R, Juarez XE, et al. Determination of the cutoff point for waist circumference that establishes the presence of abdominal obesity in Latin American men and women. Diabetes Res Clin Pract. 2011;93(2):243-7. doi: 10.1016/j.diabres.2011.05.002.
  » https://doi.org/10.1016/j.diabres.2011.05.002
• ¹⁴
  Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42(8):1298-307. PMID: 11483632.
• ¹⁵
  Ruiz-Fernández N, Espinoza M, Barrios E, Reigosa A. [Cardiometabolic factors in a comunity located at Valencia city, Venezuela]. Rev Salud Pública. 2009;11(3):383-94. PMID: 20027511.
• ¹⁶
  De Oliveria L, García E, Torres J, Rivas A. Prevalencia de Síndrome Metabólico en el Sector Olivett: El Junquito. Rev Venez Endocrinol Metab. 2006;4(3):16-42.
• ¹⁷
  Marquez-Sandoval F, Macedo-Ojeda G, Viramontes-Horner D, Fernandez Ballart JD, Salas Salvado J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011 Oct;14(10):1702-13. doi: 10.1017/S1368980010003320.
  » https://doi.org/10.1017/S1368980010003320
• ¹⁸
  Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, González C, et al. Dyslipidemias and obesity in Mexico. Salud Publica de Mexico. 2007;49(Suppl 3):S338-47. doi://dx.doi.org/10.1590/S0036-36342007000900005
  » //dx.doi.org/10.1590/S0036-36342007000900005
• ¹⁹
  Astrup A, Dyerberg J, Selleck M, Stender S. Nutrition transition and its relationship to the development of obesity and related chronic diseases. Obes Rev. 2008;9 Suppl 1:48-52. doi: 10.1111/j.1467-789X.2007.00438.x.
  » https://doi.org/10.1111/j.1467-789X.2007.00438.x
• ²⁰
  Instituto Nacional de Estatística. (INE). Venezuela (Bolivarian Republic of) Follow up survey of food consumption from 2003 to 2010 [Internet]. [Accessed on 2012 Sep 12]. Available from: http://www.ine.gov.ve/index.php?option=com_content&view=category&id=114&Itemid=
  » http://www.ine.gov.ve/index.php?option=com_content&view=category&id=114&Itemid=
• ²¹
  Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord. 2013;14(3):241-54. doi: 10.1007/s11154-013-9251-y.
  » https://doi.org/10.1007/s11154-013-9251-y
• ²²
  Nieto-Martínez R. Recomendaciones nutricionales para la poblacion venezolana. Medicina Interna (Caracas). 2015;31(3):134-6.
• ²³
  Nieto-Martínez R, Duran M, Rodriguez-Plaza L. Tratamiento no farmacológico del paciente con Dislipidemia. Recomendaciones nutricionales. Tabaquismo. Actividad física. Avances Cardiol. 2014;34(Suppl 2):S44-S57.

Publication Dates

• Publication in this collection
  Jan 2018

History

• Received
  25 Oct 2016
• Reviewed
  15 May 2017
• Accepted
  06 July 2017